NCT03727802View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

TRK-250

single and multiple doses (4 weeks)

DRUG

Placebo

single and multiple doses (4 weeks)

Trial Locations (11)

10021

Weill Cornell Medicine, New York

27403

PulmonIx LLC, Greensboro

29425

Medical University of South Carolina - Pulmonary & Critical Care Clinical Research Program, Charleston

32117

Advanced Pulmonary & Sleep Research Institute of Florida, Daytona Beach

32224

Mayo Clinic, Jacksonville

34741

Pulmonary Disease Specialists, PA, d/b/a PDS Research. Kissimmee, FL, Kissimmee

44195

Cleveland Clinic, Cleveland

75390

The University of Texas Southwestern Medical Center, Dallas

85006

Pulmonary Associates, Phoenix

90048

Cedars-Sinai Medical Center (CSMC) - Women's Guild Lung Institute, Los Angeles

95817

UC Davis Medical Center, Sacramento

All Listed Sponsors
lead

Toray Industries, Inc

INDUSTRY

NCT03727802 - Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter